Sign In
Section Navigation
Common TitleECLAIR
Official Title A Phase IIa Study to Evaluate the Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)
Phase Phase IIA
ClinicalTrials.gov NCT02076178
Treatments
Cabotegravir

Cabotegravir

Tradename:ApretudeOther Names:CAB-LA, Injectable cabotegravirClass:Integrase Strand Transfer Inhibitors (INSTI)
Categories PREP
Funding
IndustryViiV Healthcare
References
  • Markowitz M, Frank I, Grant RM, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4:e331-e340.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.